Their work presented the potential of CD19-OR-CD20 CAR as a powerful safeguard against antigen escape in CAR T treatments for wild-type and CD19− loss variant B-cell lymphomas. The gene discussed is CD19; the disease is B-cell non-Hodgkin lymphoma.